Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
Cash Flow Statements
5 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Operating Cash Flow (OCF) | -9.00 | -14.00 | -40.00 | -64.00 | -99.00 | |
| Operating Cash (Net) | -9.00 | -14.00 | -40.00 | -64.00 | -99.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | |
| Accounts Payable | - - | - - | 1.00 | 4.00 | 2.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | |
| Change | - - | 1.00 | 1.00 | 6.00 | 11.00 | |
| Other WC | - - | - - | - - | 2.00 | 8.00 | |
| Investing Activities | ||||||
| Used Cash (Net) | - - | - - | -220.00 | -10.00 | -143.00 | |
| Capital Expenditure | - - | - - | - - | - - | - - | |
| Purchases of Investments | - - | - - | -221.00 | -212.00 | -459.00 | |
| Sale/Maturity of Investment | - - | - - | 1.00 | 202.00 | 315.00 | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | - - | - - | |
| Acquisitions (Net) | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | - - | - - | - - | - - | |
| Financing Activities | ||||||
| Used Cash (Net) | - - | -22.00 | -318.00 | -248.00 | -336.00 | |
| Debt Repayment | - - | - - | -143.00 | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | 337 | |
| Issued | - - | - - | 177.00 | 248.00 | 337.00 | |
| Repurchased | - - | - - | - - | - - | - - | |
| Other Financing Activities | - - | 22.00 | 284.00 | - - | 336.00 | |
| Cash Balances | ||||||
| Begin of Period | 12.00 | 3.00 | 10.00 | 68.00 | 241.00 | |
| End of Period | 3.00 | 10.00 | 68.00 | 241.00 | 335.00 | |
| Change | -9.00 | 7.00 | 58.00 | 173.00 | 93.00 | |
| Non-Cash Balances | ||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | |
| Stock Based Compensation | - - | - - | 3.00 | 10.00 | 25.00 | |
| Other | 1.00 | -2.00 | - - | 5.00 | -10.00 | |
| Highlighted metrics | ||||||
| Free Cash Flow (FCF) | -9.00 | -14.00 | -40.00 | -64.00 | -99.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | - - | |
| Invested Capital | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - |